Intrathecal targeted drug delivery provides effective relief for cancer-related pain. However,
its validation in management of craniofacial pain remains much less widely practiced, mainly …

Abstract Introduction/Aims In 2016, nusinersen became the first disease‐modifying
medication approved by the US Food and Drug Administration (FDA) for spinal muscular …

Abstract The Coronavirus Disease (COVID-19) pandemic has reshaped clinical chronic
disease management. Patients reduced the number of physical clinic visits for regular follow …

Objectives To assist in assessment of therapy risks and benefits of targeted drug delivery
(TDD) for chronic nonmalignant pain using registry data on product performance, adverse …

Objective To investigate the opioid consumption and the healthcare resource utilization in
patients with the intrathecal drug delivery system (IDDS) therapy and the comprehensive …

Patients in pain have different levels of satisfaction. The experience of patients regarding
medication is based on their past treatment. The mental satisfaction of the patients for …

Objectives Intrathecal morphine pump (ITMP) infusion therapy is efficient in managing
chronic pain refractory to standard treatment. This study evaluates pain relief and …

To evaluate the effectiveness and safety of a cancer pain information platform combined with
semi-implantable intrathecal drug delivery systems among the patients with refractory …

This chapter explores intrathecal drug delivery (IDD) as a treatment option for intractable
pain. IDD can provide pain relief when systemic medications, surgeries, interventional …

Intrathecal drug delivery systems allow for medication delivery directly into the intrathecal
space. This route of administration allows for ready access to spinal analgesic targets. As …